Histone deacetylase inhibitors in treatment of hematological malignancies / 白血病·淋巴瘤

ABSTRACT

Histone deacetylase inhibitor (HDACi) is a novel antineoplastic agent emerging in recent years. The advent of HDACi has provided new options for the treatment of malignant tumors, parasitic and inflammatory diseases. HDACi, as single agent or in combination with other drugs, has a considerable prospect in the treatment of hematological malignancies. The use of HDACi in the treatment of hematological malignancies will be summarized in this paper based on the reports in the 58th ASH Annual Meeting.